{"groups":[{"description":"Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W","id":"FG000","title":"Part A - Flat Dosing (AF)"},{"description":"Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W","id":"FG001","title":"Part A - Age/Weight-based Dosing (AW)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"other reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Maximum clinical benefit"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Disease progression"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Only Part A was initiated prior to early study termination. Part B was not initiated."}